vs
ANI PHARMACEUTICALS INC（ANIP）与DigitalOcean Holdings, Inc.（DOCN）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是DigitalOcean Holdings, Inc.的1.0倍（$247.1M vs $242.4M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 10.6%，领先0.5%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 18.3%），DigitalOcean Holdings, Inc.自由现金流更多（$31.1M vs $29.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 14.5%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
DigitalOcean Holdings, Inc.是美国跨国科技企业及云服务提供商，总部位于美国科罗拉多州布鲁姆菲尔德，在全球布局15个数据中心，面向开发者、初创企业及中小微企业提供稳定易用的云基础设施即服务平台，助力各类技术团队高效开展业务。
ANIP vs DOCN — 直观对比
营收规模更大
ANIP
是对方的1.0倍
$242.4M
营收增速更快
ANIP
高出11.4%
18.3%
净利率更高
ANIP
高出0.5%
10.6%
自由现金流更多
DOCN
多$2.0M
$29.1M
两年增速更快
ANIP
近两年复合增速
14.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $242.4M |
| 净利润 | $27.5M | $25.7M |
| 毛利率 | — | 58.7% |
| 营业利润率 | 14.1% | 16.0% |
| 净利率 | 11.1% | 10.6% |
| 营收同比 | 29.6% | 18.3% |
| 净利润同比 | 367.5% | 40.5% |
| 每股收益（稀释后） | $1.14 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPDOCN
| Q4 25 | $247.1M | $242.4M | ||
| Q3 25 | $227.8M | $229.6M | ||
| Q2 25 | $211.4M | $218.7M | ||
| Q1 25 | $197.1M | $210.7M | ||
| Q4 24 | $190.6M | $204.9M | ||
| Q3 24 | $148.3M | $198.5M | ||
| Q2 24 | $138.0M | $192.5M | ||
| Q1 24 | $137.4M | $184.7M |
净利润ANIPDOCN
| Q4 25 | $27.5M | $25.7M | ||
| Q3 25 | $26.6M | $158.4M | ||
| Q2 25 | $8.5M | $37.0M | ||
| Q1 25 | $15.7M | $38.2M | ||
| Q4 24 | $-10.3M | $18.3M | ||
| Q3 24 | $-24.2M | $32.9M | ||
| Q2 24 | $-2.3M | $19.1M | ||
| Q1 24 | $18.2M | $14.1M |
毛利率ANIPDOCN
| Q4 25 | — | 58.7% | ||
| Q3 25 | — | 59.6% | ||
| Q2 25 | — | 59.9% | ||
| Q1 25 | — | 61.4% | ||
| Q4 24 | — | 57.1% | ||
| Q3 24 | — | 60.2% | ||
| Q2 24 | — | 61.0% | ||
| Q1 24 | — | 60.7% |
营业利润率ANIPDOCN
| Q4 25 | 14.1% | 16.0% | ||
| Q3 25 | 15.9% | 19.6% | ||
| Q2 25 | 6.6% | 16.3% | ||
| Q1 25 | 13.3% | 17.9% | ||
| Q4 24 | -2.3% | 15.9% | ||
| Q3 24 | -13.8% | 12.4% | ||
| Q2 24 | 3.7% | 11.6% | ||
| Q1 24 | 14.8% | 6.2% |
净利率ANIPDOCN
| Q4 25 | 11.1% | 10.6% | ||
| Q3 25 | 11.7% | 69.0% | ||
| Q2 25 | 4.0% | 16.9% | ||
| Q1 25 | 8.0% | 18.1% | ||
| Q4 24 | -5.4% | 8.9% | ||
| Q3 24 | -16.3% | 16.6% | ||
| Q2 24 | -1.7% | 9.9% | ||
| Q1 24 | 13.2% | 7.7% |
每股收益（稀释后）ANIPDOCN
| Q4 25 | $1.14 | $0.23 | ||
| Q3 25 | $1.13 | $1.51 | ||
| Q2 25 | $0.36 | $0.39 | ||
| Q1 25 | $0.69 | $0.39 | ||
| Q4 24 | $-0.45 | $0.21 | ||
| Q3 24 | $-1.27 | $0.33 | ||
| Q2 24 | $-0.14 | $0.20 | ||
| Q1 24 | $0.82 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $254.5M |
| 总债务越低越好 | — | $1.3B |
| 股东权益账面价值 | $540.7M | $-28.7M |
| 总资产 | $1.4B | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPDOCN
| Q4 25 | $285.6M | $254.5M | ||
| Q3 25 | $262.6M | $236.6M | ||
| Q2 25 | $217.8M | $387.7M | ||
| Q1 25 | $149.8M | $360.4M | ||
| Q4 24 | $144.9M | $428.4M | ||
| Q3 24 | $145.0M | $439.9M | ||
| Q2 24 | $240.1M | $443.1M | ||
| Q1 24 | $228.6M | $419.1M |
总债务ANIPDOCN
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ANIPDOCN
| Q4 25 | $540.7M | $-28.7M | ||
| Q3 25 | $505.8M | $-69.6M | ||
| Q2 25 | $436.8M | $-175.2M | ||
| Q1 25 | $418.6M | $-210.7M | ||
| Q4 24 | $403.7M | $-203.0M | ||
| Q3 24 | $405.9M | $-211.7M | ||
| Q2 24 | $455.8M | $-253.8M | ||
| Q1 24 | $452.0M | $-286.1M |
总资产ANIPDOCN
| Q4 25 | $1.4B | $1.8B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.3B | $1.7B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $920.8M | $1.5B | ||
| Q1 24 | $914.5M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $57.3M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $31.1M |
| 自由现金流率自由现金流/营收 | 11.8% | 12.8% |
| 资本支出强度资本支出/营收 | 0.5% | 10.8% |
| 现金转化率经营现金流/净利润 | 1.10× | 2.23× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $180.5M |
8季度趋势，按日历期对齐
经营现金流ANIPDOCN
| Q4 25 | $30.4M | $57.3M | ||
| Q3 25 | $44.1M | $95.8M | ||
| Q2 25 | $75.8M | $92.4M | ||
| Q1 25 | $35.0M | $64.1M | ||
| Q4 24 | $15.9M | $71.3M | ||
| Q3 24 | $12.5M | $73.4M | ||
| Q2 24 | $17.4M | $71.3M | ||
| Q1 24 | $18.3M | $66.7M |
自由现金流ANIPDOCN
| Q4 25 | $29.1M | $31.1M | ||
| Q3 25 | $38.0M | $88.0M | ||
| Q2 25 | $71.8M | $59.3M | ||
| Q1 25 | $32.5M | $2.1M | ||
| Q4 24 | $13.5M | $26.1M | ||
| Q3 24 | $7.7M | $16.0M | ||
| Q2 24 | $13.0M | $39.5M | ||
| Q1 24 | $13.7M | $23.0M |
自由现金流率ANIPDOCN
| Q4 25 | 11.8% | 12.8% | ||
| Q3 25 | 16.7% | 38.3% | ||
| Q2 25 | 34.0% | 27.1% | ||
| Q1 25 | 16.5% | 1.0% | ||
| Q4 24 | 7.1% | 12.7% | ||
| Q3 24 | 5.2% | 8.1% | ||
| Q2 24 | 9.4% | 20.5% | ||
| Q1 24 | 10.0% | 12.5% |
资本支出强度ANIPDOCN
| Q4 25 | 0.5% | 10.8% | ||
| Q3 25 | 2.7% | 3.4% | ||
| Q2 25 | 1.9% | 15.2% | ||
| Q1 25 | 1.3% | 29.4% | ||
| Q4 24 | 1.3% | 22.1% | ||
| Q3 24 | 3.2% | 28.9% | ||
| Q2 24 | 3.2% | 16.6% | ||
| Q1 24 | 3.3% | 23.6% |
现金转化率ANIPDOCN
| Q4 25 | 1.10× | 2.23× | ||
| Q3 25 | 1.66× | 0.60× | ||
| Q2 25 | 8.87× | 2.50× | ||
| Q1 25 | 2.23× | 1.68× | ||
| Q4 24 | — | 3.91× | ||
| Q3 24 | — | 2.23× | ||
| Q2 24 | — | 3.73× | ||
| Q1 24 | 1.00× | 4.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
DOCN
| Scalers | $84.3M | 35% |
| Scalers Plus | $69.9M | 29% |
| Builders | $64.1M | 26% |
| Learners Testers And Other | $24.1M | 10% |
